{"id":"https://openalex.org/W4394435198","doi":"https://doi.org/10.6084/m9.figshare.5127874","title":"Supplementary Material for: A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study","display_name":"Supplementary Material for: A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study","publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W4394435198","doi":"https://doi.org/10.6084/m9.figshare.5127874"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/5127874","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_A_Multidrug_Antiproteinuric_Approach_to_Alport_Syndrome_A_Ten-Year_Cohort_Study/5127874","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_A_Multidrug_Antiproteinuric_Approach_to_Alport_Syndrome_A_Ten-Year_Cohort_Study/5127874","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045803218","display_name":"Erica Daina","orcid":"https://orcid.org/0000-0002-2419-5493","observed_orcids":["https://orcid.org/0000-0002-2419-5493"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daina, E.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005075162","display_name":"Paolo Cravedi","orcid":"https://orcid.org/0000-0001-7837-0923","observed_orcids":["https://orcid.org/0000-0001-7837-0923"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cravedi, P.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052966336","display_name":"Mirella Alpa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alpa, M.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012705049","display_name":"Dario Roccatello","orcid":"https://orcid.org/0000-0002-4419-6813","observed_orcids":["https://orcid.org/0000-0002-4419-6813"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roccatello, D.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027201911","display_name":"Sara Gamba","orcid":"https://orcid.org/0000-0002-4887-890X","observed_orcids":["https://orcid.org/0000-0002-4887-890X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gamba, S.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052434587","display_name":"Annalisa Perna","orcid":"https://orcid.org/0000-0002-9257-0283","observed_orcids":["https://orcid.org/0000-0002-9257-0283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Perna, A.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051449033","display_name":"Flavio Gaspari","orcid":"https://orcid.org/0000-0001-5941-3481","observed_orcids":["https://orcid.org/0000-0001-5941-3481"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gaspari, F.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023556434","display_name":"Giuseppe Remuzzi","orcid":"https://orcid.org/0000-0002-6194-3446","observed_orcids":["https://orcid.org/0000-0002-6194-3446"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Remuzzi, G.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5059276594","display_name":"Piero Luigi Ruggenenti","orcid":"https://orcid.org/0000-0002-8394-0879","observed_orcids":["https://orcid.org/0000-0002-8394-0879"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ruggenenti, P.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10373","display_name":"Renal Transplantation Outcomes and Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2747","display_name":"Transplantation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alport-syndrome","display_name":"Alport syndrome","score":0.9959999918937683},{"id":"https://openalex.org/keywords/proteinuria","display_name":"proteinuria","score":0.6439999938011169},{"id":"https://openalex.org/keywords/albuminuria","display_name":"albuminuria","score":0.9440000057220459},{"id":"https://openalex.org/keywords/antiproteinuric-therapy","display_name":"antiproteinuric therapy","score":0.781000018119812},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.6890000104904175},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9760000109672546},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.8379999995231628},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9739999771118164},{"id":"https://openalex.org/keywords/benazepril","display_name":"benazepril","score":0.9620000123977661},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/diltiazem","display_name":"diltiazem","score":0.9950000047683716},{"id":"https://openalex.org/keywords/fluvastatin","display_name":"fluvastatin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/renal-function","display_name":"renal function","score":0.45899999141693115},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.8169999718666077},{"id":"https://openalex.org/keywords/nephropathy-progression","display_name":"nephropathy progression","score":0.593999981880188}],"concepts":[{"id":"https://openalex.org/C2776908417","wikidata":"https://www.wikidata.org/wiki/Q1331116","display_name":"Alport syndrome","level":4,"score":0.6081941723823547},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5877998471260071},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5639596581459045},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3756154477596283},{"id":"https://openalex.org/C2780368995","wikidata":"https://www.wikidata.org/wiki/Q605006","display_name":"Glomerulonephritis","level":3,"score":0.15279248356819153},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.09492260217666626}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/5127874","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_A_Multidrug_Antiproteinuric_Approach_to_Alport_Syndrome_A_Ten-Year_Cohort_Study/5127874","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.5127874","doi":"https://doi.org/10.6084/m9.figshare.5127874","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.5127874","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.5127874.v1","doi":"https://doi.org/10.6084/m9.figshare.5127874.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.5127874.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/5127874","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_A_Multidrug_Antiproteinuric_Approach_to_Alport_Syndrome_A_Ten-Year_Cohort_Study/5127874","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2049823841","https://openalex.org/W4403833412","https://openalex.org/W3030409418","https://openalex.org/W2074476571","https://openalex.org/W4406380300","https://openalex.org/W3210139906","https://openalex.org/W1107469811","https://openalex.org/W2079906751","https://openalex.org/W4398234198","https://openalex.org/W2461613212"],"abstract_inverted_index":{"Background/Aims:":[0],"Combined":[1],"ACE":[2],"inhibitor,":[3],"angiotensin-receptor-blocker,":[4],"non-dihydropyridine":[5],"calcium-channel-blocker,":[6],"and":[7,14,82,110,139,148,163,170,177,209,228,247,253],"statin":[8],"therapy":[9],"(Remission":[10],"Clinic)":[11],"reduced":[12],"proteinuria":[13],"halted":[15,254],"progression":[16,256],"in":[17,23,49,185,250,257],"non-diabetic":[18],"nephropathies,":[19],"but":[20],"their":[21],"efficacy":[22],"Alport":[24],"syndrome":[25],"(AS)":[26],"nephropathy":[27],"is":[28],"unknown.":[29],"Methods:":[30],"From":[31],"February":[32],"2004":[33],"to":[34,129,141,160,167,196,262],"September":[35],"2007,":[36],"we":[37],"included":[38],"nine":[39],"albuminuric":[40],"AS":[41,251],"adults":[42],"with":[43,72,201],"creatinine":[44,214],"clearance":[45],">20":[46],"ml/min/1.73":[47],"m2":[48],"a":[50],"single-center,":[51],"open-label,":[52],"prospective,":[53],"off-on-off":[54],"academic":[55],"study.":[56,220],"After":[57,100,191],"the":[58,67,88,106,198,216,219,222],"1-month":[59,89],"wash-out":[60,90],"from":[61,123,157,164],"RAS":[62],"inhibition":[63],"(Run-in),":[64],"patients":[65,102,252],"entered":[66],"4-month,":[68],"add-on,":[69],"treatment":[70,134],"period":[71],"benazepril":[73],"(10-20":[74],"mg/day),":[75,78,81],"valsartan":[76],"(80-160":[77],"diltiazem":[79],"(60-120":[80],"fluvastatin":[83],"(40-80":[84],"mg/day)":[85],"followed":[86,111],"by":[87],"(Recovery).":[91],"The":[92,117,237],"primary":[93],"outcome":[94],"was":[95,230,233],"albuminuria":[96,120],"at":[97,127,133,205],"month":[98],"4.":[99],"recovery,":[101,192],"were":[103,226],"kept":[104],"on":[105,181],"Remission":[107,238],"Clinic":[108,239],"protocol":[109],"until":[112,215],"July":[113],"2014":[114],"(Extension).":[115],"Results:":[116],"median":[118],"(IQR)":[119],"progressively":[121],"declined":[122],"657.7":[124],"(292.7-1,089.6)":[125],"\u03bcg/min":[126,132,144],"baseline":[128,206],"71.4":[130],"(21.7-504.9)":[131],"end":[135,217],"(p":[136,153],"=":[137],"0.009)":[138],"raised":[140],"404.3":[142],"(167.9-446.8)":[143],"after":[145],"recovery.":[146],"Albumin":[147],"IgG":[149],"fractional":[150],"clearances":[151],"significantly":[152,179],"\u2264":[154],"0.005)":[155],"decreased":[156,180],"66.9":[158],"(53.6-80.8)":[159],"9.4":[161],"(4.6-26.0)":[162],"5.1":[165],"(3.0-8.4)":[166],"1.1":[168],"(0.6-3.2),":[169],"then":[171],"recovered":[172],"toward":[173],"baseline.":[174],"Blood":[175],"pressure":[176],"lipids":[178],"treatment,":[182],"without":[183,259],"changes":[184],"inulin-measured":[186],"GFR":[187],"or":[188],"para-aminohippuric-measured":[189],"RPF.":[190],"one":[193,200,229],"patient":[194],"refused":[195],"enter":[197],"extension,":[199],"severe":[202],"renal":[203,260],"insufficiency":[204,261],"reached":[207],"ESRD,":[208],"seven":[210],"retained":[211],"normal":[212],"serum":[213],"of":[218],"At":[221],"final":[223],"visit,":[224],"three":[225],"microalbuminuric":[227],"normoalbuminuric.":[231],"Treatment":[232],"well":[234],"tolerated.":[235],"Conclusion:":[236],"approach":[240],"safely":[241],"ameliorated":[242],"albuminuria,":[243],"blood":[244],"pressure,":[245],"lipids,":[246],"glomerular":[248],"selectivity":[249],"long-term":[255],"those":[258],"start":[263],"with.":[264]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2024-04-08T00:00:00"}